Frequently Asked Questions

What does JHL Biotech do?
JHL Biotech is a biopharmaceutical company that develops its own portfolio of biosimilar products, co-develops innovative new protein therapeutics, and provides contract development and manufacturing services to select emerging biopharmaceutical firms.

What is JHL’s vision?
JHL Biotech will make world-class biologics available to all patients who need them.

What is JHL’s mission?
JHL Biotech is a vertically-integrated firm focused only on development and manufacturing of biotherapeutics. We have our own labs and manufacturing facilities, giving us control over all aspects of the biologics development and production process. By applying the latest advances in chemistry, manufacturing, and control science, we reduce the cost of producing biotherapeutics, and we make biologics more affordable by using our technology platform to create our own portfolio of biosimilars and to help others develop biotherapeutics in a cost-effective manner.

When is JHL Biotech Incorporated?
JHL Biotech, Inc. was incorporated in the Cayman Islands on December 13, 2012. In 2013, subsidiaries in both Taiwan and China were established.

Where is JHL headquartered?
JHL’s corporate headquarters is located at:Hsinchu biomedical Science park
3F, No.18, Sec. 2 Shengyi Rd., Zhubei City,
Hsinchu County 302, Taiwan (R.O.C.)

When does JHL’s fiscal year-end?
JHL’s fiscal year end is 31st December.

Who is JHL’s auditor?
PriceWaterhouse Coopers.

How do I contact JHL with additional questions or inquiries?
Please submit an inquiry via our contact form.

What is KUBio?
GE Healthcare’s KUBio is a prefabricated facility for monoclonal antibody production that is constructed, assembled and fully fitted-out in 14-18 months, which is an accelerated timeline that is significantly faster than traditional stick-built methods. KUBio also offers a suite of services in addition to the facility including: financial guidance, bioprocessing equipment selection, project coordination, and product development and qualification and repair services.

Modules are pre-built then transported to the site of choice for fast assembly, ahead of installation of GE’s FlexFactory™ biomanufacturing platform.  GE manages every stage of the project to ensure the facility and processes will be fully qualified and ready-to-run within 14 to 18 months of design approval. Using standardized equipment and an optimized layout provides the biomanufacturer with a facility that can be replicated at multiple sites, for easy tech-transfer and scale-up.

Every stage of the project is supported by GE technical expertise, including facility design, procuring and production of process equipment, installation, qualification, staff training, technical support and project management.

What is meant by the term ‘single-use modular facility’?
KUBio is produced as a number of modules, which are pre-built, then transported to the site of choice for quick and easy assembly, ahead of installation of GE’s FlexFactory™ biomanufacturing platform. FlexFactory uses disposable, single-use technologies, eliminating cleaning validation steps, and providing significant time and cost savings.

What can KUBio be used to manufacture?
At the moment, KUBio is specifically designed for the manufacture of mammalian cell based biopharmaceuticals, specifically monoclonal antibodies. There is potential for KUBio to broaden into other areas in the future, however. FlexFactory can be applied to the manufacture of other types of biologics, for example vaccines, so this is potentially an option that may be made available for KUBio.

Where is the KUBio manufactured?
The modular facility sections of the KUBio are manufactured and fitted out prior to shipping, in Germany by GE’s partner M+W. The GE Healthcare single-use components of the production line are manufactured at GE Healthcare’s global manufacturing sites in USA and Sweden.

Contact our investor relations for more information